Immune response, antibody persistence, and safety of a single dose of the quadrivalent meningococcal serogroups A, C, W-135, and Y tetanus toxoid conjugate vaccine in adolescents and adults: results of an open, randomised, controlled study

Table 2 Differences in rSBA vaccine response rate between the ACWY-TT and the Men-PS groups

Antibody	ACWY-TT		Men-PS		Difference in vaccine response rate (ACWY-TT minus Men-PS)
	N	%	N	%	% [95% CI]
rSBA-MenA	289	82.7	99	69.7	13.00 [3.52, 23.50]
rSBA-MenC	324	94.4	113	90.3	4.18 [−1.03, 11.36]
rSBA-MenW-135	326	96.3	109	91.7	4.58 [−0.07, 11.49]
rSBA-MenY	329	93.0	113	85.0	8.05 [1.72, 16.17]

ACWY-TT = group of participants who received one dose of MenACWY-TT at Month 0.
Men-PS = group of participants who received one dose of the MenACWY polysaccharide vaccine at Month 0.
Vaccine response defined as:
• rSBA titre ≥32 at Month 1 for initially seronegative participants (rSBA titre <8).
• rSBA titre at Month 1 ≥4-fold the antibody titre at Month 0 for initially seropositive participants (rSBA titre ≥8).
N = number of participants with pre- and post-vaccination results available (ATP immunogenicity cohort).
% = percentage of participants with a vaccine response.
95% CI = standardised asymptotic 95% confidence interval.
Bold = lower limits of the 95% confidence intervals of the differences in vaccine response rates, which were used to demonstrate non-inferiority.

ISSN: 1471-2334